Glenmark gets final FDA nod for migraine headache relief drug
New Delhi: Glenmark Pharma has received final nod from the USFDA to manufacture and market therapeutical equivalent of Endo Pharmaceutical's Frova tablets, used to treat migraine headaches, in the American market.
" miGlenmark Pharmaceuticals Inc has been granted final approval by the US Food and Drug Administration (USFDA) for Frovatriptan Succinate Tablets, 2.5 mg," the company said in a BSE filing.
USFDA further said the drug is "therapeutical equivalent of Endo Pharmaceutical's Frova tablets 2.5 mg."
Quoting IMS data, Glenmark said the approved product has an estimated market size of USD 87.8 million for the 12 months ended January 2016.
The company's current portfolio consists of 61 ANDAs pending approvals from the USFDA and 108 products authorised for distribution in the US.
Stock of Glenmark Pharma was trading at Rs 831.90, down 2.03 percent from the previous close on BSE.
" miGlenmark Pharmaceuticals Inc has been granted final approval by the US Food and Drug Administration (USFDA) for Frovatriptan Succinate Tablets, 2.5 mg," the company said in a BSE filing.
USFDA further said the drug is "therapeutical equivalent of Endo Pharmaceutical's Frova tablets 2.5 mg."
Quoting IMS data, Glenmark said the approved product has an estimated market size of USD 87.8 million for the 12 months ended January 2016.
The company's current portfolio consists of 61 ANDAs pending approvals from the USFDA and 108 products authorised for distribution in the US.
Stock of Glenmark Pharma was trading at Rs 831.90, down 2.03 percent from the previous close on BSE.
Next Story
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd